Health Canada has announced that all biologics, including biosimilars, will be identified by their brand names and nonproprietary names without the addition of a product-specific suffix. The regulator says that both the brand name and nonproprietary name of any biologic product should be used at all times so that products that share the same nonproprietary name can be differentiated by their brands.
Health Canada has announced that all biologics, including biosimilars, will be identified by their brand names and nonproprietary names without the addition of a product-specific suffix. The regulator says that both the brand name and nonproprietary name of any biologic product should be used at all times so that products that share the same nonproprietary name can be differentiated by their brands.
Every biologic will also continue to have a unique Drug Identification Number (DIN) that distinguishes key product information, such as brand name, manufacturer name, strength, ingredients, dosage form, and route of administration. However, DINs will no longer be used as the standard approach to identifying products in Canada.
Health Canada says that the approach will achieve the objective of distinguishing among biologics in prescribing, dispensing, and pharmacovigilance efforts without imposing an undue regulatory burden. The approach also avoid the complexity of implementing a suffix-based convention and the need to retroactively apply suffixes to the names of already-approved products.
The announcement comes after Health Canada and the Institute for Safe Medication Practices launched a February 2018 online consultation to gain stakeholder feedback on naming conventions for biologics. Among the options for naming that were proposed to stakeholders was one in which Health Canada would align with the FDA’s suffix-based naming approach; the US regulator uses 4-letter suffixes, devoid of meaning, that are appended to the nonproprietary names of biosimilars and newly approved biologics.
While the FDA has argued that its naming convention is necessary to allow for biosimilar-specific pharmacovigilance, a number of stakeholders, including prescribers, have asked the FDA to reconsider the approach, saying that a suffix should be memorable if it is to be useful, and that confusion about suffixes may result in misreported adverse events in the FDA’s Adverse Event Reporting System, thereby hindering pharmacovigilance efforts.
In their responses to the consultation, 362 stakeholders, 79% of whom were healthcare providers, were asked to rate their preferred option for naming: remaining with the status quo of using DINs, using brand names plus nonproprietary names, or implementing a suffix. Only 9% preferred the status quo, while 48% preferred using brand and proprietary names, and 34% preferred using a suffix.
In order to implement the new naming convention, Health Canada will now update its guidance documents and proceed with a regulatory amendment that twill ensure that sponsors are adequately supported in submitting unique brand names for their products. The regulator will also provide stakeholder communications on the importance of recording both brand and nonproprietary names throughout the medication use process, and will undertake activities to assist in pharmacovigilance.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.